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1. Introduction
  Diabetes is a common metabolic disorder characterized 
by hyperglycemia due to absolute or relative deficiency 
of insulin secretion from pancreatic cells[1]. Once 
hyperglycemia becomes apparent,毬-cell function 
progressively deteriorates: glucose-induced insulin 
secretion becomes further impaired and degranulation of 毬
-cells becomes evident, often accompanied by a decrease 
in the number of 毬-cells[2]. The majority of patients 
with obesity causing insulin resistance are not diabetic, 
as their capacity for 毬-cell compensation is maintained 
but, 15%-20% of these individuals become diabetic, when 
the 毬-cells lose their compensatory ability[3]. Therefore, 
one approach to preventing and treating diabetes could 
be through the enhancement of 毬-cell mass. Insulin 
deficiency stimulates lipolysis in the adipose tissue, and 
gives rise to hyperlipidemia and fatty liver[4]. Accordingly, 
although diabetes is characterized as a disease of 
carbohydrate metabolism, abnormalities of lipid and 
lipoprotein metabolism are commonly observed[5]. 
  Marine algae have begun to attract attention as rich 
sources of diverse bioactive compounds with great 
pharmaceutical and biomedical potential. Ecklonia cava 
(EC) is an abundant brown algae used as a seasoned 
vegetable in the coastal regions of Asian countries. It has 
been reported that EC extract have numerous biological 
activities, including anti-oxidative, radical scavenging, 
immunomodulatory, and anti-mutagenic activities[6-
10]. Recently, polyphenol from EC has been reported to 
inhibit 毩-amylase and 毩-glycosidase activities resulting 
in reduction of postprandial hyperglycemia in diabetic 
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mice[11]. In present study, we extended the work to examine 
the possible anti-diabetic mechanism of EC in STZ-induced 
diabetic mice as a model system of type-1 diabetes, an 
example of elevated blood lipids and insulin deficiency.
2. Materials and methods
2.1. Preparation of EC powder and extract
  EC was obtained from a local market in Seosan, Korea. 
Fresh EC was washed, dried in the shade, and ground into 
powder. The EC powder was used for the in vivo experiment 
and EC extract was used for the in vitro experiment. The 
dried powder was extracted three times with ten volumes 
of methanol at room temperature for 24 h. The combined 
extracts were centrifuged, filtered, concentrated under 
vacuum, lyophilized, and subsequently used for the 
experiment. The yield after vacuum evaporation was 12.9%.
2.2. Animals and diets
   Male ICR mice (8 wks old, Joong Ang Lab Animal Co., 
Korea) were housed in plastic cages under temperature
(24依2) ℃and light (12-h light/dark cycle) controlled 
conditions with constant humidity (55依5)%. All animals 
had free access to standard rodent pellet food, except when 
fasted before experiments. The study has been approved 
by Animal Ethics Committee of Kyunghee University, and 
carried out along the Korea National Institutes of Health 
Guidelines on the care and use of laboratory animals. The 
mice were randomly divided into 6 groups (n = 10); normal 
control (NC), normal mice fed 3% EC powder (NE3), normal 
mice fed 5% EC (NE5), diabetic control (DC), diabetic mice 
fed 3% EC (DE3), and 5% EC (DE5). 
  Diabetes was induced by a single intraperitoneal injection 
of STZ (Sigma, St. Louis, USA, 90 mg/kg in citrate buffer, 
pH 4.5). Normal groups received the buffer only. Tail 
bleeds were performed 24 h post-injection, and animals 
with a blood glucose concentration above 300 mg/dL were 
considered to be diabetic and used in this study.   
2.3. Oral glucose tolerance test and biochemical analysis
  At the end of 4 wks of experimental period, mice were 
fasted overnight and orally administered with glucose 
(1.5 g/kg). Blood samples were collected from the tail at 
various time points (0-90 min) after glucose loading, and 
blood glucose levels were measured by One Touch Basic 
Glucose Measurement System (Life Scan Inc., USA). Mice 
were killed by decapitation immediately 90 min after blood 
samples were taken. Serum concentrations of glucose, 
aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), total cholesterol (TC), HDL-cholesterol (HDL-C), 
and triglyceride (TG) were measured using commercially 
available kits (Youngdong Pharmaceutical Co., Korea). 
Serum LDL-cholesterol (LDL-C) levels were calculated by 
Friedwald equation[12]. Serum insulin concentrations were 
determined by using radioimmunoassay kit (Boehringer 
Mannheim, Germany). The hepatic lipids were extracted 
using the procedure developed by Folch et al[13], and the TC 
and TG concentrations were measured using same kits as 
serum. 
2.4. Histological analysis
  Pancreatic and hepatic tissue fragments were fixed in 
10% neutralized formalin solution for 24 h. After fixing, 
the tissues were dehydrated, embedded in paraffin, and 
sectioned with 5 毺m thickness (Leica, Wetzlar, Germany). 
Histological staining of 毬-cells using aldehyde fuchsin 
staining, and hematoxylin and eosin (H&E) staining for 
hepatic tissue were performed.
2.5. In vitro insulin secretion
  Pancreatic islet cells were isolated from male mice by 
collagenase digestion[14]. Twenty islets were pre-incubated 
in Krebs-Ringer Bicarbonate (KRB) buffer, pH 7.4, 
supplemented with serum albumin (3 mg/mL) and glucose 
(3 mM) for 30 min at 37 ℃ under humidified atmosphere 
of 5% CO2 in air. The islets were treated with various 
concentrations of EC extract in 16 mM glucose KRB buffer 
for 60 min at 37 ℃. Insulin concentration in each medium 
was determined using an ELISA procedure (Boehringer 
Mannheim Diagnostics, Germany). 
2.6. Statistical analysis
 
  Data were expressed as Mean依SEM. One-way ANOVA was 
used to determine treatment effects. Differences among 
means were inspected using Duncan's multiple range test 
and were considered to be significant at P < 0.05.
3. Results
3.1. Hypoglycemic effect 
  
  Induction of diabetes caused significant weight loss 
resulting in negative body weight gain in diabetic mice 
(Table 1). Interestingly, administration of EC significantly 
and dose-dependently decreased the weight gain in normal 
mice but prevents the weight loss in diabetic mice. Initial 
blood glucose levels were 3.6-fold elevated in STZ-diabetic 
mice (DC) compared with normal control (NC), and EC 
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supplement decreased hyperglycemia in a dose-dependent 
manner. Accordingly, administration of EC increased serum 
insulin levels of diabetic mice in a dose-dependent manner. 
EC supplementation at 5% of the diet for 4 wks elevated 
the serum insulin concentration to 86% of the normal level. 
Normal mice were not affected in serum glucose and insulin 
levels by EC supplement.
  The results of the light microscopy investigation 
demonstrated that the pancreas of the normal mice showed 
normal pancreatic architecture while diabetic mice revealed 
relatively small, atrophied probably due to the reduction 
in the number of the cells, lightly stained, ambiguity of 
their verges, and degranulation of cells (Figure 1). EC 
supplemented diabetic mice exhibited obvious amelioration 
in histological signs. Strong staining and increased size of 
islets displaying less degenerative changes compared with 
DC group. 
Figure 1.  Images of histologically-stained 毬-cells in pancreas.
Pancreases from normal control (A), normal mice treated with 3% EC 
( B), normal mice treated with 5% EC (C), STZ-diabetic control (D), 
diabetic mice treated with 3% EC (E), or diabetic mice treated with 
5% EC (F) were stained with aldehyde fuchsin staining. Scale bar 
indicates 100 毺m. 
 
  To assess glucose homeostasis and insulin sensitivity in 
EC supplemented mice, we next performed OGTT. As shown 
in Figure 2, glucose load in NC produced rapid increase in 
blood glucose levels from 113依4 to 254依15 mg/dL at 30 min 
and returned to baseline values within 90 min. STZ-induced 
diabetic mice demonstrated basal hyperglycemia (394依14 
mg/dL) which remained above 400 mg/dL during all time 
points determined. The peak increase in serum glucose 
concentrations in diabetic mice was observed after 60 min of 
glucose treatment, while that of normal mice observed after 
30 min, indicating delayed glucose homeostasis in diabetic 
mice. EC exerted no significant effect on the basal glucose 
or OGTT of normal mice. In contrast, 3% and 5% of EC 
supplementation in diabetic mice resulted in a significant 
dose-dependent reduction in fasting blood glucose levels 
combined with a significant improvement in glucose 
tolerance showing similar patterns as normal control group. 

















NC        NE3      NE5        DC       DE3      DE5
Figure 2.  Effect of EC on oral glucose tolerance test. 
Normal control mice (NC); normal mice supplemented with 3% EC 
(NE3); normal mice supplemented with 5% EC (NE5); STZ-diabetic 
control mice (DC); diabetic mice supplemented with 3% EC (DE3); 
diabetic mice supplemented with 5% EC (DE5).
 * P<0.05 vs. NC, † P<0.05 vs. DC.
3.2. Hypolipidemic effect 
  TG, TC, and LDL- C concentrations in the serum were 
significantly higher in STZ-diabetic mice than normal 
control mice (Table 2). The supplementation of EC dose-
dependently suppressed these parameters in both normal 
and diabetic mice. The serum TG, TC, and LDL-C levels 
of DE5 group were decreased by 72%, 53%, and 78%, 
respectively. HDL-C concentrations of DC were significantly 
lower than NC, and EC supplementation dose-dependently 
increased the HDL-C levels exhibiting 1.8-fold increase in 
DE5 group compared with DC group. EC treatments fail to 
affect HDL-C concentrations in normal mice.
  The activities of liver function markers, serum AST and 
ALT concentrations in DC were significantly increased by 
1.7- and 2.1-fold, respectively, compared with those of NC 
group (Table 2). EC supplementation dose-dependently 
reduced these marker enzyme activities in STZ-diabetic 
mice resulting in normal levels in DE5 group. Elevated liver 
TG and cholesterol levels in DC were dose-dependently 
decreased by EC administration resulting in normal levels of 
these parameters. 
  The results of the histological investigation of the liver 
are shown in Figure 3. DC group showed the accumulation 
of hepatic lipid droplets, and severe steatosis compare to 
NC group which exhibited normal hepatic histology. The 
clear vacuoles would have contained lipid in the living 
cells, however the histological fixation caused it to be 
dissolved and hence only empty spaces remain. In the EC 
supplemented groups, reduced lipid droplets were observed 
in a dose-dependent manner showing similar morphological 
liver condition to that of the normal group.
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Figure 3.  Effect of EC on hepatic tissue morphology. 
Representative picture of H & E stained sections of liver tissue from 
normal control (A), normal mice treated with 3% EC (B), normal mice 
treated with 5% EC (C), STZ-diabetic control (D), diabetic mice 
treated with 3% EC (E), or diabetic mice treated with 5% EC (F). 
Scale bar indicates 50 毺m.
3.3. In vitro glucose-induced insulin secretion in pancreatic 
islets 
  To elucidate the mechanism of anti-diabetic effect of 
EC, the glucose-induced insulin secretion was examined 
in hyperglycemic condition (16 mM) using pancreatic 
毬-islet cells. The data in Table 3 shows that insulin 
secretion increased with increasing concentrations of EC 
extract (P<0.05). The EC-boosted glucose-induced insulin 
secretion peaked at 50 毺g/mL of EC extract in the medium, 
and declined significantly at EC concentrations higher than
50 毺g/mL.
4. Discussion
  STZ-induced diabetes in adult animals has been 
used as a model for insulin-dependent diabetes and 
hypercholesterolemia, and has been shown to be sensitive 
Table 1 
Effects of  EC on body weight, blood glucose and insulin. 
Group Weight gain (g/4wk) Serum glucose(mg/dL) Serum insulin(ng/mL)
NC   1.70依0.10 108.00依2.00 1.28依0.03
NE3 -2.60依0.10+ 106.00依2.00 1.25依0.03
NE5 -3.20依0.10+ 102.00依4.00 1.30依0.01
DC -5.70依0.10* 394.00依8.00* 0.50依0.01*
DE3 -1.60依0.20*+ 263.00依9.00*+ 0.86依0.03*+
DE5 -1.90依0.20*+ 198.00依10.00*+ 1.09依0.02*+
NC: normal control mice; NE3: normal mice supplied with 3% EC; NE5: normal mice fed 5% EC; DC: STZ-diabetic mice; DE: diabetic mice fed 
3% EC; DE5: diabetic mice fed 5% EC. 
* P<0.05 vs. NC, † P<0.05 vs. DC.
 
Table 2
 Effects of EC on serum lipid profiles in STZ-diabetic mice  
Group TG (mg/dL) TC(mg/dL) LDL-C(mg/dL) HDL-C(mg/dL) AST(U/mL) ALT(U/mL) TG (mg/g) Chol (mg/g)
NC  92.2依1.7 151.4依5.4 40.3依5.4 92.6依2.5  77.3依8.4 36.0依3.2 20.1依2.0 5.6依0.5
NE3  87.8依4.0  133.6依3.6+   26.3依3.6+ 89.9依2.7  71.0依3.9 34.1依3.9 19.3依3.4 5.0依0.3
NE5   80.4依3.8+  121.0依3.1+  24.2依3.1+ 86.7依7.5  64.8依6.0 28.5依5.4 17.5依2.7  4.5依0.3+
DC 244.6依4.5*  279.0依6.5* 188.3依6.5*  41.7依4.7* 133.5依8.4*  76.0依5.7*  35.4依4.4*  9.1依1.3*
DE3    81.3依2.0*+  149.1依3.1+   68.4依3.1*+    64.4依0.8*+     92.9依6.0*+   52.9依6.2*+  20.7依4.1+  6.8依0.6+
DE5    68.2依1.8*+   130.4依5.4*+  40.6依5.4+    76.1依0.3*+   80.4依5.0+  37.9依7.7+  17.9依2.2+  5.1依0.5+
NC: normal control mice; NE3: normal mice supplied with 3% EC; NE5: normal mice fed 5% EC; DC: STZ-diabetic mice; DE: diabetic mice fed 
3% EC; DE5: diabetic mice fed 5% EC. 
* P<0.05 vs. NC, † P<0.05 vs. DC.
 
Table 3
 Effect of EC on glucose-induced insulin secretion in pancreatic islets
EC extract (毺g/mL) Insulin (毺U/mL) % baseline
   0   52.8 依 4.2 100.0 依 0.0
  25 106.3 依 3.6 201.3 依 3.1
  50 168.9 依 8.4 319.9 依 6.4
100 124.5 依 5.1 235.8 依 6.2
300   86.7 依 2.9 164.2 依 3.1
500   76.8 依 2.1 145.5 依 2.5
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to cholesterol metabolism. We examined the insulinotrophic 
and lipid lowering potential of EC in STZ-diabetic mice. To 
our knowledge, this is the first time to show the protective 
effect on pancreatic 毬-cell and hypolipidemic effect of EC 
in diabetic mice.
  The change in blood glucose levels in response to an oral 
glucose load has been used clinically for the diagnosis 
of diabetes and in research to evaluate the hypoglycemic 
agents. In OGTT study, EC supplementation exhibited 
significant reduction in blood glucose levels combined 
with a significant improvement in glucose tolerance.  After 
an oral ingestion of glucose, the maintenance of glucose 
tolerance depends on insulin secretion, hepatic glucose 
production, glucose absorption in the digestive tract, and 
glucose uptake by peripheral tissues[15]. In the present 
study, the anti-hyperglycemic activity of EC could be due 
to its insulinotrophic action, as increased insulin secretion 
in isolated pancreatic islet cells with EC treatment and 
elevated serum insulin levels in EC treated diabetic mice 
were observed. Histopathological examination of pancreatic 
sections also revealed degenerated and necrotic cells in 
DC mice, while EC treatment significantly alleviated these 
abnormalities and increased 毬-cell mass. In support of 
this association, 毬-cell death and a reduction in number 
of islets were observed in pancreas of diabetic rats and 
hypoglycemic plant extract control the 毬-cell damage and 
increased the number of islets[16,17]. Therefore, the possible 
mechanism by which EC brings about its hypoglycemic 
effect may be by increasing the insulin level from the 
protective effect of pancreatic islets to prevent the loss of 
毬-cell mass, and stimulation of insulin secretion from the 
remaining 毬-cells. The increase in serum insulin level after 
EC treatment could be linked to more than one mechanism. 
The possible mechanism includes the quantitative changes 
in pancreatic 毬-cells by differentiation and proliferation of 
residual pancreatic 毬-cells. It may be also attributable to 
increased insulin synthesis or secretion by residual 毬-cells 
similar to that observed after glibenclamide administration. 
EC also acts as a hepatoprotective agent as shown in liver 
function marker enzymes, suggesting enhanced transport of 
blood glucose to peripheral tissues and its utilization, which 
may be another mechanism of action.
  Since lipid abnormalities is the major cause of 
cardiovascular disease in diabetes, the ideal treatment 
for diabetes should have a favourable effect on the lipid 
profile in addition to glycemic control. In views of this, we 
investigated the effect of EC on serum and hepatic lipid 
parameter. The altered lipid and lipoprotein profiles were 
significantly reversed after 4 weeks of EC supplementation 
to the diabetic mice. Insulin insufficiency is responsible 
for the derangement of lipid and lipoprotein metabolism[18]. 
Insulin decreases TG levels and increases HDL-C through 
activation of lipoprotein lipase[19,20]. Insulin also increases 
receptor-mediated removal of LDL-C and hence decreased 
activity of insulin during diabetes leads to increased levels 
of serum LDL-C and consequently hypercholesterolemia[21]. 
Therefore, significant control in the serum lipid levels 
in EC treated diabetic mice might have been due to the 
insulinotrophic action upon EC administration. On the other 
hand, decreased glucose disposal during diabetes leads to 
increased utilization of fatty acids for energy production, 
which consequently results in increased formation of acetyl 
coenzyme A and thus of lipids. Hence, the increased insulin 
levels brought about by EC supplementation indicates the 
possible effect on sensitizing tissues like skeletal muscle 
and adipose tissue for uptake of glucose and thus protecting 
lipid formation.
  The increased TG and TC levels and decreased HDL-C 
are known factors associated with coronary heart disease 
(CHD)[22,23]. As EC supplementation produced a favourable 
effect on these factors, this suggests that it may help to 
prevent the progression of CHD. Recent studies suggest that 
TG itself is independently related to CHD, and that most 
of the anti-hypercholesterolemic drugs do not decrease 
TG levels[24,25]. However, EC lowered TG as well as TC and 
LDL-C to near normal level after 4 weeks of administration. 
This strong effect on diabetic hyperlipidemia could be 
through its control on hyperglycemia, because the level of 
glycemic control is the major determinant of TG and VLDL-C 
concentrations[26-32]. 
  An elevated ALT and AST appears to be a consequence 
of hepatocyte damage, and thus is considered a result of 
insulin resistance[33]. Our data showed that EC had a curative 
effect on liver damage indicated by normalized serum AST 
and ALT levels, liver lipid levels, and hepatic histological 
observation in STZ-diabetic mice after EC supplementation. 
Therefore, improvement of the body weight loss in diabetic 
mice with EC supplement might be from the beneficial effect 
on the metabolic state in diabetes via improved pancreatic 
and liver function. 
  Natural polyphenols are abundant constituents of 
seaweeds, and EC has been known as a polyphenol-rich 
seaweed[34]. It has been reported that polyphenols from 
various plants induce pancreatic insulin secretion[35], 
and improve dyslipidemia in animal models[36]. Although 
the major components that possess the activity in the EC 
were not precisely identified in this study, it would be of 
considerable interest to further elucidate the mechanism 
and component(s) underlying the action of EC. 
  In conclusion, this study clearly demonstrated that 
treatment with EC ameliorates hyperglycemia and improves 
glucose handling capacity in STZ-diabetic mice in a dose-
dependent manner, at least in part, by preventing loss of 
毬-cell mass and increase of insulin secretary capacity. 
This is especially important in preclinical models of type 2 
diabetes that are characterized by a progressive decline of 
pancreatic function due to subsequent 毬-cell failure and 
loss of 毬-cell mass. In addition, EC treatment is a potent 
and efficacious lipid-lowering agent in diabetic mice.
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